National Diabetes Audit
Key findings about the quality of care for people with diabetes in England incorporating registrations from Wales : abridged report for the audit period 2004/05
Classmark: 616.462
Check availablility by searching the library catalogue directly from this page using the search box in the grey column to the right (only from a Trust computer).
This week's Diabetes Bulletin...
...
Friday 25 April 2008
Supplement: Glycaemic Control, Hypoglycaemic Symptoms and Effectiveness of Treatment Intensification in Type 2 Diabetes Mellitus
Diabetes, Obesity and Metabolism
Volume 10, Issue s1, June 2008
Foreword
Treatment intensification in patients with type 2 diabetes
Anthony H. Barnett
pages iii–iii
Original Articles
Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis
J. Belsey G. Krishnarajah
pages 1–7
Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
F. Álvarez Guisasola, P. Mavros, G. Nocea, E. Alemao, C. M. Alexander D. Yin
pages 8–15
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
P. Vexiau, P. Mavros, G. Krishnarajah, R. Lyu D. Yin
pages 16–24
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
F. Álvarez Guisasola, S. Tofé Povedano, G. Krishnarajah, R. Lyu, P. Mavros D. Yin
pages 25–32
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications
J. Chen, E. Alemao, D. Yin J. Cook
pages 33–42
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz, M. Gouveia, J. Chen, G. Nocea, K. Jameson, J. Cook, G. Krishnarajah, E. Alemao, D. Yin H. Sintonen
pages 43–55
Volume 10, Issue s1, June 2008
Foreword
Treatment intensification in patients with type 2 diabetes
Anthony H. Barnett
pages iii–iii
Original Articles
Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis
J. Belsey G. Krishnarajah
pages 1–7
Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
F. Álvarez Guisasola, P. Mavros, G. Nocea, E. Alemao, C. M. Alexander D. Yin
pages 8–15
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
P. Vexiau, P. Mavros, G. Krishnarajah, R. Lyu D. Yin
pages 16–24
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
F. Álvarez Guisasola, S. Tofé Povedano, G. Krishnarajah, R. Lyu, P. Mavros D. Yin
pages 25–32
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications
J. Chen, E. Alemao, D. Yin J. Cook
pages 33–42
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz, M. Gouveia, J. Chen, G. Nocea, K. Jameson, J. Cook, G. Krishnarajah, E. Alemao, D. Yin H. Sintonen
pages 43–55
Self monitoring of blood glucose in patients with type 2 diabetes
BMJ.com
The NHS is spending £100 million a year to help people with non-insulin treated type 2 diabetes monitor their own blood sugar levels, but the process is more likely to make them depressed than provide any long term health benefits. Access the two research papers and editorial by following the links from bmj.com's Research channel. There are also Rapid Responses to these online first papers.
Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial
Responses
Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial
The NHS is spending £100 million a year to help people with non-insulin treated type 2 diabetes monitor their own blood sugar levels, but the process is more likely to make them depressed than provide any long term health benefits. Access the two research papers and editorial by following the links from bmj.com's Research channel. There are also Rapid Responses to these online first papers.
Self monitoring of blood glucose in type 2 diabetes
Responses
Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial
Responses
Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
Diabetes, Obesity and Metabolism
Original Articles
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
B. F. Burkey, P. K. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes J. E. Foley
Original Articles
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
B. F. Burkey, P. K. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes J. E. Foley
BMJ Learning module - Hypoglycaemia in people with type 1 diabetes mellitus
Hypoglycaemia is a common and dangerous condition - this module outlines how to diagnose, manage and prevent it as well as giving an update on hypoglycaemic unawareness and autonomic failure. Click on the link to complete it today.
http://learning.bmj.com/learning/search-result.html?moduleId=6052503
To access BMJ learning modules you need to log in using your Athens password. The first time you access the site you will also need to register.
http://learning.bmj.com/learning/search-result.html?moduleId=6052503
To access BMJ learning modules you need to log in using your Athens password. The first time you access the site you will also need to register.
Labels:
education,
hyperglycemia
Training tomorrow's doctors in diabetes...
BMC Medical Education - Latest articles
Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK: a multi-centre survey
By Jyothis T George, David A Warriner, Jeffrin Anthony, Kavitha S Rozario, Sinu Xavier, Edward B Jude and Gerard A Mckay
Aim: To assess the confidence, practices and perceived training needs in diabetes care of post-graduate trainee doctors in the UK. Methods: An anonymised postal questionnaire using a validated 'Confidence Rating' (CR) scale was applied to aspects of diabetes care and administered to junior doctors from three UK hospitals. The frequency of aspects of day-to-day practice was assessed using a five-point scale with narrative description in combination with numeric values. Respondents had a choice of 'always' (100%), 'almost always' (80-99%), 'often' (50-79%), 'not very often' (20-49%) and 'rarely' (less than 20%). Yes/No questions were used to assess perception of further training requirements. Additional 'free-text' comments were also sought. Results: 82 doctors completed the survey. The mean number of years since medical qualification was 3 years and 4 months, (range: 4 months to 14 years and 1 month). Only 11 of the respondents had undergone specific diabetes training since qualification. 4(5%) reported 'not confident' (CR1), 30 (37%) 'satisfactory but lacked confidence' (CR2), 25 (30%) felt 'confident in some cases' (CR3) and 23 (28%) doctors felt fully confident (CR4) in diagnosing diabetes. 12 (15%) doctors would always, 24 (29%) almost always, 20 (24%) often, 22 (27%) not very often and 4 (5%) rarely take the initiative to optimise glycaemic control. 5 (6%) reported training in diagnosis of diabetes was adequate while 59 (72%) would welcome more training. Reported confidence was better in managing diabetes emergencies, with 4 (5%) not confident in managing hypoglycaemia, 10 (12%) lacking confidence, 22 (27%) confident in some cases and 45 (55%) fully confident in almost all cases. Managing diabetic ketoacidosis, 5 (6%) doctors did not feel confident, 16 (20%) lacked confidence, 20 (24%) confident in some cases, and 40 (50%) felt fully confident in almost all cases. Conclusions: There is a lack of confidence in managing aspects of diabetes care, including the management of diabetes emergencies, amongst postgraduate trainee doctors with a perceived need for more training. This may have considerable significance and further research is required to identify the causes of deficiencies identified in this study.
Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK: a multi-centre survey
By Jyothis T George, David A Warriner, Jeffrin Anthony, Kavitha S Rozario, Sinu Xavier, Edward B Jude and Gerard A Mckay
Aim: To assess the confidence, practices and perceived training needs in diabetes care of post-graduate trainee doctors in the UK. Methods: An anonymised postal questionnaire using a validated 'Confidence Rating' (CR) scale was applied to aspects of diabetes care and administered to junior doctors from three UK hospitals. The frequency of aspects of day-to-day practice was assessed using a five-point scale with narrative description in combination with numeric values. Respondents had a choice of 'always' (100%), 'almost always' (80-99%), 'often' (50-79%), 'not very often' (20-49%) and 'rarely' (less than 20%). Yes/No questions were used to assess perception of further training requirements. Additional 'free-text' comments were also sought. Results: 82 doctors completed the survey. The mean number of years since medical qualification was 3 years and 4 months, (range: 4 months to 14 years and 1 month). Only 11 of the respondents had undergone specific diabetes training since qualification. 4(5%) reported 'not confident' (CR1), 30 (37%) 'satisfactory but lacked confidence' (CR2), 25 (30%) felt 'confident in some cases' (CR3) and 23 (28%) doctors felt fully confident (CR4) in diagnosing diabetes. 12 (15%) doctors would always, 24 (29%) almost always, 20 (24%) often, 22 (27%) not very often and 4 (5%) rarely take the initiative to optimise glycaemic control. 5 (6%) reported training in diagnosis of diabetes was adequate while 59 (72%) would welcome more training. Reported confidence was better in managing diabetes emergencies, with 4 (5%) not confident in managing hypoglycaemia, 10 (12%) lacking confidence, 22 (27%) confident in some cases and 45 (55%) fully confident in almost all cases. Managing diabetic ketoacidosis, 5 (6%) doctors did not feel confident, 16 (20%) lacked confidence, 20 (24%) confident in some cases, and 40 (50%) felt fully confident in almost all cases. Conclusions: There is a lack of confidence in managing aspects of diabetes care, including the management of diabetes emergencies, amongst postgraduate trainee doctors with a perceived need for more training. This may have considerable significance and further research is required to identify the causes of deficiencies identified in this study.
Labels:
education,
full text (electronic)
Pediatric Diabetes Volume 9, Issue 2, April 2008
Editorial
Solar power to prevent type 1 diabetes?
Klaus Badenhoop
pages 79–80
Original Articles
Time series analysis of ultraviolet B radiation and type 1 diabetes in Newfoundland
Scott Sloka, Marie Grant Leigh Anne Newhook
pages 81–86
Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus
Dana C Perantie, Audrey Lim, Jenny Wu, Patrick Weaver, Stacie L Warren, Michelle Sadler, Neil H White Tamara Hershey
pages 87–95
Nutritional management of children and adolescents on insulin pump therapy a survey of Australian Practice
Carmel E Smart, Clare E Collins Julia Schoonbeek
pages 96–103
Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress
Raanan Shamir, Haifa Kassis, Marielle Kaplan, Tova Naveh Naim Shehadeh
pages 104–109
Peripheral neuropathy is an early complication of type 2 diabetes in adolescence
Zacharoula Karabouta, Susan Barnett, Julian PH Shield, Fiona J Ryan Elizabeth C Crowne
pages 110–114
Dyslipidemia in children with type 2 diabetes vs. obesity
Ron S Newfield, Asheesh K Dewan Sonia Jain
pages 115–121
Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus
Maria V Karantza, Steven D Mittelman, Fred Dorey, Sara Samie, Kevin Kaiserman, Mary Halvorson Francine R Kaufman
pages 122–126
Number of islet autoantibodies present in newly diagnosed type 1 diabetes children born to non-diabetic mothers is affected by islet autoantibodies present at birth
Maria Elfving, Bengt Lindberg, Kristian Lynch, Majvi Månsson, Göran Sundkvist, Åke Lernmark Sten A Ivarsson
pages 127–134
Maternal diet during pregnancy and islet autoimmunity in offspring
Molly M Lamb, Mark A Myers, Katherine Barriga, Paul Z Zimmet, Marian Rewers Jill M Norris
pages 135–141
Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)
Diabetes Research In Children Network (DirecNet) Study Group*
pages 142–147
Use of CoZmonitor® in youth with type 1 diabetes*
Erin Cobry, H. Peter Chase, Patricia Burdick, Kim McFann, Hannah Yetzer Laura Scrimgeour
pages 148–151
Review Article
Innate and adaptive autoimmunity in type 1 diabetes
Michael P Morran, Marcia F McInerney Massimo Pietropaolo
pages 152–161
Case Report
Triple diabetes: coexistence of type 1 diabetes mellitus and a novel mutation in the gene responsible for MODY3 in an overweight adolescent
Sasigarn A Bowden Robert P Hoffman
pages 162–164
ISPAD Clinical Practice Consensus Guidelines 2006-2007
Assessment and management of hypoglycemia in children and adolescents with diabetes
William Clarke, Timothy Jones, Arleta Rewers, David Dunger Georgeanna J Klingensmith
pages 165–174
Solar power to prevent type 1 diabetes?
Klaus Badenhoop
pages 79–80
Original Articles
Time series analysis of ultraviolet B radiation and type 1 diabetes in Newfoundland
Scott Sloka, Marie Grant Leigh Anne Newhook
pages 81–86
Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus
Dana C Perantie, Audrey Lim, Jenny Wu, Patrick Weaver, Stacie L Warren, Michelle Sadler, Neil H White Tamara Hershey
pages 87–95
Nutritional management of children and adolescents on insulin pump therapy a survey of Australian Practice
Carmel E Smart, Clare E Collins Julia Schoonbeek
pages 96–103
Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress
Raanan Shamir, Haifa Kassis, Marielle Kaplan, Tova Naveh Naim Shehadeh
pages 104–109
Peripheral neuropathy is an early complication of type 2 diabetes in adolescence
Zacharoula Karabouta, Susan Barnett, Julian PH Shield, Fiona J Ryan Elizabeth C Crowne
pages 110–114
Dyslipidemia in children with type 2 diabetes vs. obesity
Ron S Newfield, Asheesh K Dewan Sonia Jain
pages 115–121
Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus
Maria V Karantza, Steven D Mittelman, Fred Dorey, Sara Samie, Kevin Kaiserman, Mary Halvorson Francine R Kaufman
pages 122–126
Number of islet autoantibodies present in newly diagnosed type 1 diabetes children born to non-diabetic mothers is affected by islet autoantibodies present at birth
Maria Elfving, Bengt Lindberg, Kristian Lynch, Majvi Månsson, Göran Sundkvist, Åke Lernmark Sten A Ivarsson
pages 127–134
Maternal diet during pregnancy and islet autoimmunity in offspring
Molly M Lamb, Mark A Myers, Katherine Barriga, Paul Z Zimmet, Marian Rewers Jill M Norris
pages 135–141
Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)
Diabetes Research In Children Network (DirecNet) Study Group*
pages 142–147
Use of CoZmonitor® in youth with type 1 diabetes*
Erin Cobry, H. Peter Chase, Patricia Burdick, Kim McFann, Hannah Yetzer Laura Scrimgeour
pages 148–151
Review Article
Innate and adaptive autoimmunity in type 1 diabetes
Michael P Morran, Marcia F McInerney Massimo Pietropaolo
pages 152–161
Case Report
Triple diabetes: coexistence of type 1 diabetes mellitus and a novel mutation in the gene responsible for MODY3 in an overweight adolescent
Sasigarn A Bowden Robert P Hoffman
pages 162–164
ISPAD Clinical Practice Consensus Guidelines 2006-2007
Assessment and management of hypoglycemia in children and adolescents with diabetes
William Clarke, Timothy Jones, Arleta Rewers, David Dunger Georgeanna J Klingensmith
pages 165–174
Accepted for restricted use within NHS Scotland
Scottish Medicines Consortium (SMC): http://www.scottishmedicines.org/
* vildagliptin (Galvus) for type 2 diabetes as dual oral therapy in combination with metformin, when the addition of sulphonylureas is not appropriate
* insulin glulisine (Apidra Solostar) for the treatment of adults, adolescents and children of 6 years and above with diabetes mellitus, where treatment with insulin is required. Use is restricted to adult patients for whom treatment with this insulin analogue is appropriate, and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.
* insulin glargine (Lantus Solostar) for the treatment of adults, adolescents and children of 6 years and above with diabetes mellitus, where treatment with insulin is required. It may be used in patients in whom treatment with this insulin analogue is appropriate and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.
* vildagliptin (Galvus) for type 2 diabetes as dual oral therapy in combination with metformin, when the addition of sulphonylureas is not appropriate
* insulin glulisine (Apidra Solostar) for the treatment of adults, adolescents and children of 6 years and above with diabetes mellitus, where treatment with insulin is required. Use is restricted to adult patients for whom treatment with this insulin analogue is appropriate, and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.
* insulin glargine (Lantus Solostar) for the treatment of adults, adolescents and children of 6 years and above with diabetes mellitus, where treatment with insulin is required. It may be used in patients in whom treatment with this insulin analogue is appropriate and in whom the use of a pre-filled pen offers advantages over a pen and cartridge device.
Labels:
treatment
Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry
Pediatric Diabetes (Online early articles)
Original Articles
Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry
Jørn V Sagen, Lise Bjørkhaug, Janne Molnes, Helge Ræder, Louise Grevle, Oddmund Søvik, Anders Molven Pål R Njølstad
Original Articles
Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry
Jørn V Sagen, Lise Bjørkhaug, Janne Molnes, Helge Ræder, Louise Grevle, Oddmund Søvik, Anders Molven Pål R Njølstad
Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales....
Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia
Diabetes Research and Clinical Practice, 2007 Dec, vol. 78, no. 3, p.
392-7
Becker-T, Moldoveanu-A, Cukierman-T, Gerstein-HC.
OBJECTIVE: Despite its ubiquitous use, the value of subcutaneous
insulin-by-glucose sliding scales (SISS) for the management of in-
patient hyperglycemia has not been carefully assessed. METHODS: The
medical charts of 391 patients >45 years of age admitted with
pneumonia from January 2003 to May 2004 who had a recorded glucose
within 24h of admission and who did not have active cancer,
tuberculosis or AIDS were reviewed. Abstracted data included
demographics, clinical characteristics, admission and daily glucose
levels, medications, SISS use and clinical outcomes. The primary
outcome was pre-defined as a composite of in-hospital mortality,
cardiovascular complications, sepsis or ICU admission. RESULTS:
Compared to patients not prescribed an SISS during the admission, the
47 patients prescribed an SISS had a higher rate of the following
outcomes: primary outcome (OR=2.55; 95% CI 1.38-4.73); cardiovascular
complications or death (OR=1.86; 95% CI 0.99-3.49), sepsis or ICU
admission (OR=4.98; 95% CI 2.38-10.42). The relationship between
sliding scale use and the primary outcome was statistically
significant, even after controlling for age, sex, diabetes, steroids,
CHF and COPD (P<0.0001). Patients receiving a sliding scale had mean
in-hospital glucose values of 11.83mmol/L versus 7.2mmol/L (P<0.0001)
in patients not receiving an insulin sliding scale. CONCLUSION: Among
patients admitted to a medical ward with pneumonia, an SISS is
associated with higher glucose levels and poorer clinical outcomes.
Diabetes Research and Clinical Practice, 2007 Dec, vol. 78, no. 3, p.
392-7
Becker-T, Moldoveanu-A, Cukierman-T, Gerstein-HC.
OBJECTIVE: Despite its ubiquitous use, the value of subcutaneous
insulin-by-glucose sliding scales (SISS) for the management of in-
patient hyperglycemia has not been carefully assessed. METHODS: The
medical charts of 391 patients >45 years of age admitted with
pneumonia from January 2003 to May 2004 who had a recorded glucose
within 24h of admission and who did not have active cancer,
tuberculosis or AIDS were reviewed. Abstracted data included
demographics, clinical characteristics, admission and daily glucose
levels, medications, SISS use and clinical outcomes. The primary
outcome was pre-defined as a composite of in-hospital mortality,
cardiovascular complications, sepsis or ICU admission. RESULTS:
Compared to patients not prescribed an SISS during the admission, the
47 patients prescribed an SISS had a higher rate of the following
outcomes: primary outcome (OR=2.55; 95% CI 1.38-4.73); cardiovascular
complications or death (OR=1.86; 95% CI 0.99-3.49), sepsis or ICU
admission (OR=4.98; 95% CI 2.38-10.42). The relationship between
sliding scale use and the primary outcome was statistically
significant, even after controlling for age, sex, diabetes, steroids,
CHF and COPD (P<0.0001). Patients receiving a sliding scale had mean
in-hospital glucose values of 11.83mmol/L versus 7.2mmol/L (P<0.0001)
in patients not receiving an insulin sliding scale. CONCLUSION: Among
patients admitted to a medical ward with pneumonia, an SISS is
associated with higher glucose levels and poorer clinical outcomes.
Labels:
hyperglycemia,
SISS,
treatment,
trials
Diabetes, Obesity and Metabolism Volume 10, Issue 5, May 2008
Review Articles
Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or Pandora’s box?
A. Liew, J. H. McDermott, F. Barry T. O’Brien
pages 353–366
The effect of thiazolidinediones on adiponectin serum level: a meta-analysis
N. Riera-Guardia D. Rothenbacher
pages 367–375
Original Articles
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes*
J. Rosenstock, S. Sankoh J. F. List
pages 376–386
Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial*
M. Davies, F. Lavalle-González, F. Storms R. Gomis (AT.LANTUS Study Group)
pages 387–399
Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise
H. Yokoyama, K. Mori, M. Emoto, T. Araki, M. Teramura, K. Mochizuki, T. Tashiro, K. Motozuka, Y. Inoue Y. Nishizawa
pages 400–407
Beta cells in type 2 diabetes a crucial contribution to pathogenesis
Kathrin Maedler
pages 408–420
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up
M. Alvarsson, G. Sundkvist, I. Lager, K. Berntorp, E. Fernqvist-Forbes, L. Steen, T. Örn, M. A. Holberg, N. Kirksæther V. Grill
pages 421–429
National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study
E. Mannucci, M. Monami, B. Cresci, L. Pala, G. Bardini, M. G. Petracca, I. Dicembrini, A. Pasqua, E. Buiatti C. M. Rotella
pages 430–435
Correspondence
Letter to the Editor
Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
A. Garber
pages 436–437
News and Views
News and Views
Iskandar Idris
pages 438–440
Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or Pandora’s box?
A. Liew, J. H. McDermott, F. Barry T. O’Brien
pages 353–366
The effect of thiazolidinediones on adiponectin serum level: a meta-analysis
N. Riera-Guardia D. Rothenbacher
pages 367–375
Original Articles
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes*
J. Rosenstock, S. Sankoh J. F. List
pages 376–386
Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial*
M. Davies, F. Lavalle-González, F. Storms R. Gomis (AT.LANTUS Study Group)
pages 387–399
Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise
H. Yokoyama, K. Mori, M. Emoto, T. Araki, M. Teramura, K. Mochizuki, T. Tashiro, K. Motozuka, Y. Inoue Y. Nishizawa
pages 400–407
Beta cells in type 2 diabetes a crucial contribution to pathogenesis
Kathrin Maedler
pages 408–420
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up
M. Alvarsson, G. Sundkvist, I. Lager, K. Berntorp, E. Fernqvist-Forbes, L. Steen, T. Örn, M. A. Holberg, N. Kirksæther V. Grill
pages 421–429
National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study
E. Mannucci, M. Monami, B. Cresci, L. Pala, G. Bardini, M. G. Petracca, I. Dicembrini, A. Pasqua, E. Buiatti C. M. Rotella
pages 430–435
Correspondence
Letter to the Editor
Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
A. Garber
pages 436–437
News and Views
News and Views
Iskandar Idris
pages 438–440
Parent-adolescent communication and diabetes: an integrative review
Journal of Advanced Nursing
Volume 62, Issue 2, April 2008
pages 140–162
Parentadolescent communication and diabetes: an integrative review
REVIEW PAPER
Carol Dashiff, Traci Hardeman & Rhonda McLain
Volume 62, Issue 2, April 2008
pages 140–162
Parentadolescent communication and diabetes: an integrative review
REVIEW PAPER
Carol Dashiff, Traci Hardeman & Rhonda McLain
Labels:
paediatric
Subscribe to:
Posts (Atom)
